polimorfisme genètic del metabolisme de fàrmacs ... · snodgrass wr, potter wz, jollow dj, reiser...
TRANSCRIPT
281
178. Martínez Roig A, Camí J, LLorens Terol J, de la
Torre R, Perich F. Acetylation phenotype and
hepatotoxicity in the treatment of tuberculosis
in children. Pediatrics. 77. 912-915, 1986.
179. Martínez Jordà R. Estudio del fenotipo acetilador en
el País Vasco. Actas 5a. Reunión de la Asociación
Española de Farmacología. Tenerife, 1980.
180. Mazze RI, Woodruff RE, Heerdt E. Isoniaz id-induced
enflurane defluorination in humans.
Anesthesiology , 57 , 528, 1982.
181. McGeer PL, McGeer EG, Suzuki JS. Aging and
extrapyramidal function. Arch Neurol, 34, 33-35,
1977.
:E
182. McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward
JW. Pharmacokinetics and beta-blocking effects of
timolol in poor and extensive metabolizers of
debrisoquin. Clin Pharmacol Therf 3_8, 409-413,
1985.
282
183. McLaren EH, Burden AC, Moorhead PJ. Acetylator
phenotype in diabetic neuropathy. Br Med J. 2.,
291-293, 1977.
184. McQueen EG. Pharmacological basis of adverse drug
reactions. A Avery (dir) Drug Treatment, 2a ed,
pp 202-235. Adis Press, Sydney.
185. Mellstròm B, Swe J, Bertilsson L, Sjòqvist F.
Amitriptyline metabolism: associaton with debrisoquin
hydroxylation in nonsmokers. Clin Pharmacol Therf
39. 369-371, 1986.
186. Mellstròm B, Bertilsson L, Swe J, Schulz HV,
Sjòqvist F. E-and Z-10-hydroxylation of
nortriptyline: relationship to polymorphic
debrisoquine hydroxylation. Clin Pharmacol Ther.
3_0, 189-193, 1981.
187. Miller ME, Garland WA, Min BH, Ludwick BT, Ballard
RH, Levy RH. Clonazepam acetylation in fast and slow
283
acetylators. Clin Pharmacol Ther. 30f 343-347,
1981.
188. Miller ME. Acetylator phenotype in bladder cancer.
Lancet. 2., 1348, 1982.
189. Miller ME, Cosgriff JM. Acetylator phenotype in human
bladder cancer. J Urolf I30f 65-66, 1983.
190. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA,
Snodgrass WR, Potter WZ, Jollow DJ, Reiser HR.
Increased incidence of isoniazid hepatitis in rapid
acetylators: possible relation to hydrazine metabolites
Clin Pharmacol Ther. 18, 70-79, 1975.
191. Mitchell SC, Waring RH, Haley CS, Idle JR, Smith RI.
Genetic aspects of the polymodally distributed
sulphoxidation of S-carboxymethyl-L-cysteine in man.
Br J Clin Pharmacol. 18. 507-521, 1984.
192. Molin L, Larsson R, Karlsson E. Evaluation of the
284
sulphapyridine acetylator phenotyping test in healthy
subjects and in patients with cardiac and renal
diseases. Acta Med Scandf 201, 217-222, 1977.
193. Moore MR. International review of drugs in acute
porphyria - 1980. Int J Biochem. 12, 1089-1097, 1980.
194. Moore MR. McColl KEL, Goldberg A. Drugs and the acute
porphyrias. Trends Pharmacol Sci. 2., 330-334, 1981.
195. Morris RJ, Freed CR, Kohler PF. Drug acetylation
phenotype unrelated to development of spontaneous
systemic lupus erythematosus. Arthr Rheum. 22,
777-780, 1979.
196. Motulski AG, Yoshida A, Stamatoyannopoulos G.
Glucose-6-phosphate dehydrogenase variants. Ann NY
Acad Sci. 179r 636, 1971.
197. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E,
Wilkinson GR, Branch RA. Interethnic differences in
genetic polymorphism of debrisoquin and mephenytoin
285
between Japanese and Caucasian populations. Clin
Pharmacol Ther. 38. 402-408, 1985.
198. O'Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin
ML. Hereditary transmission of exceptional resistance
to coumarin anticoagulant drugs. The first reported
kindred. N Encfl J Med. 721. 809, 1964.
199. Gates NS, Shah RR, Idle JR, Smith RL. Genetic
polymorphism of phenformin 4-hydroxylation. Clin
Pharmacol Ther. 32, 81-89, 1982.
200. Dates NS, Shah RR, Idle JR, Smith RL. Influence of
oxidation polymorphism on phenformin kinetics and
dynamics. Clin Pharmacol Ther. 34, 827-834, 1983.
201. Oka M, Seppala O. Acetylation phenotype in rheumatoid
arthritis. Scand J Rheumatol. 7., 29-30, 1978.
202. Olsen H, Morland J. Ethanol-induced increase in drug
acetylation in man isolated rat liver cells. Br Med Jf
2, 1260-1262, 1978.
286
203. Otton SV, Inaba T, Kalow W. Inhibition of sparteine
oxidation in human liver by tricyclic antidepressants
and other drugs. Life SciF 32. 795-800, 1983.
204. Otton SV, Inaba T, Kalow W. Competitive inhibition of
sparteine oxidation in human liver by
beta-adrenoceptor antagonists and other
cardiovascular drugs. Life Sci. 34, 73-80, 1984.
205. Osborne KH, De George FV. Genetic basis of
morphological variation, an evaluation and aplication
of the twin study method. Harvard University Press.
Cambridge Mass, 1959.
206. Panayi GS, Huston G, Shah RR, Mitchell SC, Idle JR,
Smith , Waring RH. Deficient sulphoxidation status
and D-penicillamine toxicity. Lancet. JL, 414,
1983.
207. Paulsen O, Nilsson LG. Distribution of acetylator
phenotype in relation to age and sex in Swedish
patients. Eur J Clin Pharmacolf 28, 311-315, 1985.
287
208. Paykel ES, West PS, Rowan PR, Parker RR. Influence of
acetylator phenotype on antidepressant effects of
phenelzine. Br J Psychiatry, 141, 243-248, 1982.
209. Peart GF, Boutagy J, Shenfield GN. Debrisoquin
oxydation in an Australian population. Br J Clin
Pharmac. 21, 465-471, 1986.
210. Penno MB, Vesell ES. Monogenic control of variations
in antipyrine metabolite formation: new polymorphism
of hepatic drug oxidation. J Clin Invest. 71.
1698-1709, 1983.
211. Perry Jr HM. Late toxicity to hydralazine resembling
systemic lupus erythematosus or rheumatoid arthritis.
Am J Med. 54, 58-71, 1973.
212. Perry Jr HM, Tan EM, Cordoby S, Sahamato A.
Relationship of acetyltransferase activity to
antinuclear antibodies and toxic symptoms on
hypertensive patients treated with hydralazine.
J Laborat Clin Med. 76. 114-125, 1970.
288
213. Peters JH, Gordon GR, Murray JF. Metabolic
disposition of dapsone in African leprosy patients.
Leprosy Rev, 50. 7-19, 1979.
214. Peters JH, Murray JF, Gordon GR, Gelber RH. Dapsone
in saliva and plasma of man. Pharmacology. 22f
162-171, 1981.
215. Petrakis NL, Wiesenfeld SL, Sams RJ, Collen MF,
Cutler JL, Siegelaub AB. Prevalence of sickle-cell
trait and glucose-6-phosphate dehydrogenase
deficiency. N Enql J Med. 282. 767, 1970.
216. Philips PA, Rogers HJ, Millis RR, Rubens RD, Cartwight
RA. Acetylator status and its relationship to breast
cancer and other diseases of the breast. Eur J Cancer
Clin Oncol. 21, 1701-1706, 1987.
217. Poirier J, Roy M, Campanella G, Cloutier T, Paris S.
Debrisoquine metabolism in parkinsonism patients
treated with antihistamine drugs. Lancet. 2.,
386, 1987.
289
218. Poland A, Glover E. 2,3,7,8,-Tetrachlorodibenzo-p-dioxin:
a potent inducer of delta-aminolevulinic acid synthetase,
Science. 179f 476, 1973.
219. Pontiroli AE, De Pascua A, Bonisoli L, Pozza G.
Ageing and acetylator phenotype as determined by
administration of sulphadimidine. Eur J Clin
Pharmacol. 28f 485-486, 1985.
220. Prankerd TAJ. The Red Cell. Thomas. Springfield, 1961.
221. Prankerd TAJ. Glucose-6-phosphate dehydrogenase
deficiency. Proc R Soc Med. 57, 506-508, 1964.
222. Price Evans DA, Eze LC, Whibley EJ. The association
of the slow acetylator phenotype with bladder
cancer. J Med Genetics. 20, 330-333, 1983.
223. Price Evans DA, Harmer D, Downham DY, Whibley EJ,
Idle JR, Ritchie J, Smith RL. The genetic control of
sparteine and debrisoquine metabolism in man with new
290
methods of analysing bimodal distributions. J Med
Genetics. 20f 321-329, 1983.
224. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith
RL. A family and population study of the genetic
polymorphism of debrisoquine oxidation in a white
British population. J Med Genetics. 17, 102-105,
1980.
225. Price Evans DA, Manley KA, McKussick VÀ. Genetic
control of isoniazid metabolism in man. Br Med Jf
2., 485-491, 1960.
226. Price Evans DA, White TA. Human acetylation
polymorphism. J Laborat Clin Medf 63, 394-403,
1964.
227. Raghupati Sarma G, Kailasam S, Nair NGK, Narayana
ASL, Tripathy SP. Effect of prednisolone and
rifampicin on isoniazid metabolism in slow and rapid
inactivators of isoniazid. Antimicr Ag Chemother, 18,
661-666, 1980.
291
228. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ.
Polymorphic ability to metabolize propranolol alter
4-hydroxypropranolol levels but not beta blockade.
Clin Pharmacol Ther. 36, 51-56, 1984.
229. Ramsay LE, Silas JH, Ollerenshaw JD, Tucker GT,
Phillips FC, Freestone S. Should the acetylator
phenotype be determined when prescribing hydralazine
for hypertension. Eur J Clin Pharmacol. 26P
39-42, 1984.
230. Rao KVN, Mitchison DA, Nair NGK, Prema K, Tripathy
SP. Sulphadimidine acetylation test for
classificaction of patients as slow or rapid
inactivators of isoniazid. Br Med J. 3., 495-497,
1970.
231. Redondo FL, Miralles E, Bergón E, Ramos V.
Acetilación hepática en la población española
(carta). Gastroenterol Hepatol. 1, 107, 1980.
292
232. Reece PA, Cozamanis I, Zacest R. Kinetics of
hydralazine and its main metabolites in slow and fast
acetylators. Clin Pharmacol Ther. 28, 769-778,
1980.
233. Reidenberg MM. The clinical induction of systemic
lupus erythematosus and lupus-like illnesses. Arthr
Rheumat. 24. 1005-1009, 1981.
234. Reidenberg MM, Drayer DE, Levy M, Warner H.
Polymorphic acetylation of procainamide in man. Clin
Pharmacol Ther. 17. 722-730, 1975.
235. Reidenberg MM, Levy M, Drayer DE, Zylber-Katz E,
Robbins WC. Acetylator phenotype in idiophatic
systemic lupus erythematosus. Arthr Rheumat. 23,
569-573, 1980.
236. Reidenberg MM, Martin JH. The acetylator phenotype of
patients with systemic lupus erythematosus. Drug
Metab Disp. 2, 71-73, 1974.
293
237. Ritchie JC, Sloan TP, Idle JR, Smith RL.
Toxicological implications of polymorphic drug
metabolism. In Environmental chemicals, enzyme
function and human disease. CIBA Foundation
Symposium, 76, 219-224, 1980.
238. Robson JM, Sullivan FM. Antituberculosis drugs.
Pharmacol Rev, 15, 169-223, 1963.
239. Roden DN, Reele SB, Higgins SB, Mayol RF, Gammans RE,
Dates JA, Woosley RL. Total suppression of ventricular
arrhythmias by encainide. N Engl J Med. 302.
878-882, 1980.
240. Roden DN, Reele SB, Higgins SB, Smith R, Gates JA,
Woosley RL. Antiarrhythmic efficacy, pharmacokinetics
and safety of N-acetylprocainamide in man. Am J
Cardiol. 46. 463-468, 1980.
241. Rose S. The relationship of acetylation phenotype to
treatment with MAOIs: A review. J Clin
Psychopharmacol, 2., 161-164, 1982.
294
242. Rothfield NF, Bierer WF, Garfield JW. Isoniazid
induction of antinuclear antibodies, a prospective
study. Ann Intern Med. 88. 650-652, 1978.
243. Sanders GL, Rawlins MD. Phenelzine: acetylator status
and clinical response. Br J Clin Pharmacol. 7_,
451-452, 1979.
244. Saucedo R, Mayor B, Puche E. Estudio del fenotipo
acetilador en Andalucía. Rev Clin Esp. 177,
75-77, 1985.
245. Schmid B, Bircher J, Preising R, Kupfe A. Polymorphic
dextrometorfan metabolism: cosegregation of oxydative
O-demethylation with debrisoquin hydroxylation. Clin
Pharmacol Ther. 38. 618-624, 1985.
246. Schroeder P, Kligaard NA, Simonsen E. significance of
the acetylation phenotype and the therapeutic effect
of procainamide. Eur J Clin Pharmacol. 15, 63-68,
1979.
V.--
295
247. Scott EM. The relation of diaphorase of human
erythrocytes to inheritance of methemoglobinemia.
J Clin Invest. 39. 1176, 1960.
248. Scott J, Poffenbarger PL. Pharmacogenetics of
tolbutamide metabolism in humans. Diabetes, 28,
41-51, 1979.
249. Shah RR, Gates NS, Idle JR, Smith RL. Beta-blockers
and drug oxidation status. Lancet, I, 508-509,
1982.
250. Shah RR, Gates NS, Idle JR, Smith RL, Lockhart JDF.
Impaired oxidation of debrisoquine in patients with
perhexiline neuropathy. Br Med J. 284f 295-299,
1982.
251. Sharp ME, Wallace S, Hindmarsh KW, Brown MA.
Acetylator phenotype and serum levels of
sulphapyridine in patients with inflammatory bowel
disease. Eur J Clin Pharmacolf 21. 243-250, 1981.
296
252. Shepherd AMM, Lin M-S, McNay J, Ludden T, Musgrave G.
Determinants of response to intravenous hydralazine
in hypertension. Clin Pharmacol Therf 30.
773-781, 1981.
253. Shepherd AMM, McNay JL, Ludden TM, Lin M-S, Musgrave
GE. Plasma concentration and acetylator phenotype
determine response total hydralazine. Hypertension. 3.,
580-585, 1981.
254. Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL,
Marten TR The disposition of debrisoquine in hypertensive
patients. Br J Clin Pharmacol. 5_, 27-34, 1978.
255. Singlas E, Goujet MA, Simon P. Pharmacokinetics of
perhexiline maléate in anginal patients with and
without peripheral neuropathy. Eur J Clin
Pharmacol. 14. 195-201, 1978.
256. Sjòqvist F, Borga O, Orme MLE. Fundamentals of
clinical pharmacology. A Avery (dir), Drug
297
Treatmentf 2» ed, 32-33. ADIS Press, Sydney, 1980.
257. Sloan TP, Idle JR, Smith RL. Influence of D"/D'
alíeles regulating debrisoquine oxidation of
phenytoin hydroxylation. Clin Pharmacol Ther. 29f
493-497, 1981.
258. Sloan TP, Lancaster R, Shah R, Idle JR, Smith RL.
Genetically determined oxidation capacity and the
disposition of debrisoquine. Br J Clin Pharmacol.
15, 443-450, 1983.
259. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL.
Polymorphism of carbon oxidation of drugs and
clinical implications. Br Med J, 2f 655-657,
1978.
260. Smith RL, Idle JR, Mahgoub AA, Sloan TP, Lancaster R.
Genetically determined defects of oxidations at
carbon centres of drugs. Lancet. 1, 943-944, 1978.
298
261. Sonnhag C, Karlsson E, Hed J. Procainamide-induced
erythematosus-like syndrome in relation to acetylator
phenotype and plasma levels of procainamide. Acta
Med Scand. 206. 245-251, 1979.
262. Spina E, Steiner E, Ericsson, Sjòqvist F.
Hydroxylation of demethylimipramine: dependence on
the debrisoquin hydroxylation phenotype. Clin
Pharmacol Ther. 41. 314-319, 1987.
263. Spina E, Bigersson C, von Bahr Ch, Ericsson,
Steiner E, Sjòqvist F. Phenotyping consistency in
hydroxylation of demethylimipramine and debrisoquine
in healthy subjects in human liver microsomes. Clin
Pharmacol Ther. 36. 677-682, 1984.
264. Steiner E, Iselius L, Alvan G, Lindsten J, Sjòqvist
F. A family study of genetic and environmental factors
determining polymorphic hydroxylation of debrisoquin.
Clin Pharmacol Ther. 3_8, 394-401, 1985.
299
265. Steiner E, Alván G, Garle M, Maguire JH, Lind M,
Nilsson S-O, Tomson T, McClanahan JS, Sjòqvist F. The
debrisoquin hydroxylation phenotype does not predict
the metabolism of phenytoin. Clin Pharmacol Therf
42., 326-333, 1987.
266. Steiner E, Bertilsson L, Swe J, Berthing I, Sjòqvist
F. Polymorphic debrisoquine hydroxylation in 757
Swedish subjects. Clin Pharmacol Ther, 44, 431-435,
1988.
267. Stephen PJ, Williamson J. Drug-induced parkinsonism
in the elderly. Lancet. 2., 1082-1083, 1984.
268. Steventon G, Williams AC, Waring RH, Pall HS, Adams
D. Xenobiotic metabolism in motoneuron disease.
Lancet. 2_, 644-647, 1988.
269. Strandberg I, Boman G, Hasster L, Sjòqvist F.
Acetylator phenotype in patients with
hydralazine-induced lupoid syndrome. Acta Med
300
Scand. 200. 362-371, 1976.
270. Suhardjono D, Boutagy JS, Shenfield GM. Influence of
blood glucose on acetylation status (Abstract). Clin
Exp Pharmacol Phvsiol. Suppl 8, 64, 1984.
271. Surana MK, Mathur AK, Banerjee K, Agarwal TD.
Correlation between acetylator phenotype and
neuropathy in diabetes mellitus patients. J
Ass Physicians India, 30, 437-439, 1982.
272. Syvlahti EKG, Lindberg R, Kallio J, de Vocht M.
Inhibitory effects of neuroleptics on debrisoquine
oxidation in man. Br J Clin Pharmacol, 22, 89-92,
1986.
273. Szórády I, Santa A. Drug hydroxylator phenotype in
Hungary. Eur J Clin Pharmacol. 32f 325, 1987.
274. Talseth T, Landmark KH. Polymorphic acetylation of
sulphadimidine in normal and uraemic man. Eur J Clin
301
Pharmacol , 11, 33-36, 1977
275. Tang BK, Kadar D, Kalow W. An alternative test for
acetylator phenotyping with caffeine. Clin Pharmacol
Ther. 42., 509-513, 1987.
276. Thorn S, Farrow PR, Santoso B, Alberti KGMM, Rawlins
MD. Effects of oral glucose in lime juice on isoniazid
kinetics. Br J Clin Pharmacol. 11, 423P, 1981.
277. Timbrell JA, Harland SJ, Facchini V. Polymorphic
acetylation of hydralazine. Clin Pharmacol Ther.
28. 350-355, 1980.
278. Timbrell JA, Wright JM, Baillie TA. Monoacetyl-
hydrazine as a metabolite of isoniazid in
man. Clin Pharmacol Ther. 22, 602-608, 1977.
279. Valsalan VC, Cooper GL. Carbamazepine intoxication
caused by interaction with isoniazid. Br Med J.
285. 261-262, 1982.
302
280. Vandenburg MJ, Wright P, Holmes J, Rogers HJ, Ahmad
RA. The hypotensive response to hydralazine, in
triple therapy, is not related to acetylator
phenotype. Br J Clin Pharmacol. 13. 747-750,
1982.
281. Vansant J, Woosley RL, John JT, Sergent JS. Normal
distribution of acetylation phenotypes in systemic
lupus erythematosus. Arthr Rheumat. 21. 192-195,
1978.
282. Vasko MR, Bell RD, Daly DD, Pippenger CE. Inheritance
of phenytoin hypometabolism: a kinetic study of one
family. Clin Pharmacol Therf 27, 96-103, 1980.
283. Vesell ES, Ng L, Passanant! GT, Chase TN. Inhibition
of drug metabolism by levodopa in combination with a
dopa-decarboxylase inhibitor. Lancet, 2., 370, 1971.
284. Vesell ES. Why individuals vary in their response to
drugs, 1980. Trends Pharmacol Sci. JL, 349-351,
1980.
303
285. Vesell ES, Penno MB. Assessment of methods to
identify sources of interindividual pharmacokinetic
variations. Clin Pharmacokin. jJ, 378-409, 1983.
286. Voguel F, Motulski AG. Human genetics. Problems and
approaches. Springer Verlag, Berlin, Heid NY, 1979.
287. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R,
Calne DR. Parkinson's disease in 65 pairs of twins
and in a set of quadruplets. Neurology, 33.
815-824, 1983.
288. Waring RH, Mitchell SC, Shah RR, Idle JR, Smith RL.
Polymorphic sulphoxidation of S-carboxymethyl-L-
-cysteine in man. Biochem Pharmacolf 31, 3151-3154,
1982.
289. Wasserman RH, Taylor AN. Vitamin 03-induced
calcium-binding protein in chick intestinal mucose.
Science, 152, 791, 1966.
•EJft> >; '. >,.
304
290. Weber WW, Hein DW. Clinical pharmacokinetics of
isoniazid. Clin Pharmacokin. 94, 401-422, 1979.
291. Weber WW, Glowinski IB. Acetylation. A Jakoby
(dir), Enzymatic basis for detoxication. 169-186.
Academic Press, Nova York, 1980.
292. Weinshilboum RM. Biochemical genetics of
catecholamines in humans. Mayo Clin Proc.
58. 319-330, 1983.
293. White TA, Price Evans DA. The acetylation of
suphamethazine and sulphamethoxypyridazine by human
subjects. Clin Pharmacol Ther. 9_, 80-88, 1968.
294. Winters RW, Graham JB, Williams TF, McFalls VW,
Burnett CH. A genetic study of familial
hypophosphatemia and vitmamin D resistant rickets.
Transact Ass Amer Physicians. 70. 234, 1957.
295. Wiholm BE. El sistema sueco de detección y
305
cuantificación de reacciones adversas a medicamentos.
A Laporte J i Laporte JR (dirs), Avances en
terapéutica, vol 15. 44-63. Salvat. Barcelona,
1988.
296. Wolf H, Lower Jr GM, Bryan GT. Role of
N-acetyltransferase phenotype in human susceptibility
to bladder carcinogenic arylamines. Scand J Urol
Nephrol. 14. 161-165, 1980.
297. Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR,
Smith RL. Debrisoquine hydroxylation polymorphism
among Ghanaians and Caucasians. Clin Pharmacol
Ther. 26. 584-591, 1979.
298. Woolhouse NM, Atu-Taylor LC. Influence of double
genetic polymorphism on response to sulfamethazine.
Clin Pharmacol Ther. 31. 377-383, 1982.
299. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr
K, Gates JA. Effect of acetylator phenotype on the
-', Yv*.-:-
306
rate at which procainamide induces antinuclear
antibodies and the lupus syndrome. N Encfl J Med,
!, 1157-1159, 1978.
300. Woosley R, Roden DM, Dai G, Wang T, Altenberg D, Gates J,
Wilkinson G. Co-inheritance of the polymorphic metabolism
of encainide and debrisoquine. Clin Pharmacol Ther. 39 ,
282-287, 1986.
301. Woosley RL, Roden DM, Duff HG, Carey BL, Wood AJJ,
Wilkinson GR. Coinheritance of deficient oxidative
metabolism of encainide and debrisoquine. Clin Res,
29. 501A, 1981.
302. Ylitalo P, Ruosteenoja R, Leskinen O, Mets-Ketel T.
Significance of acetylator phenotype in
pharmacokinetics and adverse effects of procainamide.
Eur J Clin Pharmacol. 25. 791-795, 1983.
303. Yoshida A. Hemolytic anemia and G6PD deficiency.
Science. 179. 532, 1973.
307
304. Young JR. Acetylator status and liver function
profile changes in labyrinthine ischaemia patients
with thymoxamine. Int J Med Res, 8., 356-357,
1980.
305. Zacest R, Koch-Weser J. Relation of hydralazine
plasma concentration to dosage and hypotensive
action. Clin Pharmacol Therf 13, 420-425, 1972.
306. Zidek Z, Janku I. Estrogen dependent differences in
the rat. Pharmacology. 19f 209-214, 1979.
307. Zinkham WH, Childs B. Effect of vitamin K and
naphthalene metabolites on glutathione metabolism of
erythrocytes from normal newborns and patients with
naphthalene hemolytic anemia. Am J Pis Child. 94,
420, 1957.
'V,-.